Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Profit After Tax (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Profit After Tax for 4 consecutive years, with -$107.2 billion as the latest value for Q4 2025.

  • For Q4 2025, Profit After Tax fell 12.33% year-over-year to -$107.2 billion; the TTM value through Dec 2025 reached -$107.3 billion, down 12.38%, while the annual FY2025 figure was -$107.3 billion, 12.38% down from the prior year.
  • Profit After Tax was -$107.2 billion for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • The five-year high for Profit After Tax was $37.0 million in Q3 2024, with the low at -$188.8 billion in Q4 2023.
  • Historically, Profit After Tax has averaged -$33.4 billion across 4 years, with a median of -$40.1 million in 2022.
  • The largest annual shift saw Profit After Tax soared 180.25% in 2024 before it tumbled 588.04% in 2025.
  • Over 4 years, Profit After Tax stood at -$142.1 billion in 2022, then crashed by 32.87% to -$188.8 billion in 2023, then soared by 49.43% to -$95.5 billion in 2024, then fell by 12.33% to -$107.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$107.2 billion in Q4 2025, -$19.7 million in Q3 2025, and -$30.3 million in Q2 2025.